AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 10 - (NewsRx.com & NewsRx.net) -- Cellegy Pharmaceuticals, Inc., (CLGY) announced that in the The Journal of Gender-Specific Medicine results were reported from a study, supported by Cellegy Pharmaceuticals, regarding the use of topical nitroglycerin (NTG) for the treatment of women with vulvodynia.
The paper was authored by Kathleen Walsh and her coinvestigators at the University of California, Los Angeles Medical Center.
Vulvodynia is categorized by symptoms of vulvar pain, regardless of etiology. This pain is usually cyclic, occurring just before or during menses and is exacerbated by sexual intercourse. It is estimated that vulvodynia affects as many as 15% of women in the general gynecologic population. Currently, there are no approved medical treatments indicated for the treatment of vulvodynia.
This open label study included 34 women diagnosed with vulvodynia. Topical treatment with NTG was initiated in the clinic and was continued at home for 4 to 6 weeks. Patients were instructed to use topical nitroglycerin five to 10 minutes before sexual relations and, as part of the study, patients completed pre and post treatment questionnaires.
An improvement in pain was reported by 91.5% of patients (31/34). Significant decreases in pain intensity (p
Jennifer Berman, one of the study's ...
Source: HighBeam Research, Positive results reported using nitroglycerin for female sexual...